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C-type viruses are vertically transmitted, endogenous viruses of mice and the 
ecotropic viruses have been etiologically associated with spontaneous leukemia 
in AKR mice  (1-4) and radiation-induced leukemias in a  variety of strains of 
mice (5-7). 
The genetics of the expression of murine leukemia viruses (MuLV)  ~  in AKR mice has 
been extensively analyzed (8, 9), and the influence of this expression on the development 
of spontaneous lymphomas has been examined (10). The latter studies are particularly 
significant since they demonstrated that, in AKR mice genetically crossed with strains 
expressing low levels of virus, there is a direct correlation between the level of infectious 
MuLV and the incidence of lymphoma. Interestingly, however, such lymphomas are only 
induced by extremely high levels of infectious virus that persist throughout the life span 
of the mice. 
Whole-body irradiation of a variety of inbred strains of mice has been shown to induce 
thymic lymphomas with the pathological characteristics of tumors that spontaneously 
arise in AKR mice (7, 11). In contrast to lymphomas in AKR mice, these lymphomas are 
not generally associated with high levels of infectious MuLV, and cell-free extracts from 
the primary lymphomas are only weakly leukemogenic with a long latency period (5, 6, 
12). Continued passage of lymphoma extracts in vivo greatly enhances leukemogenic 
activity and decreases the latency period. From this type of propagation the radiation 
leukemia virus (RADLV) has been obtained and is extremely leukemogenic (7). RADLV 
grown in vitro is serologically cross-reactive with Gross or AKR MuLV and differs only 
by its Fv-1 tropism, since it is a B-tropic virus (7, 13, 14), although N-tropic viruses can 
also be isolated from Fv-1  b C57BL/6 mice. Although the expression of viral antigens in 
RADLV-induced lymphomas can be readily detected with indirect immunofluorescence, 
virus expression in most radiation-induced lymphomas is not detectable by this technique 
(15, 16). The presence of RADLV in these thymomas, however, is suggested by a variety 
of indirect experimental approaches (7), including the ability to obtain a B-tropic virus 
after continued blind passage of tumor extracts in vitro. This led to the hypothesis that 
primary tumors in irradiated C57BL/Ka mice are induced by the activation of a latent 
endogenous, ecotropic MuLV, which replicates in the tumor but at relatively low levels 
(7, 16). 
In previous studies we analyzed the humoral immune response against endogenous 
* Supported  by the National Cancer Institute under contract no. N01-C0-25423 with Litton 
Bionetics, Inc. Frederick,  Md. 
1 Abbreviations used in thispaper: MuLV, murine leukemia virus; RADLV, radiation leukemia 
virus(es); RIP, radioimmune precipitation. 
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ecotropic viruses in a  variety of inbred strains of mice (17-21).  In general, this immune 
response  is  characterized  by  antibodies  directed  against  the  virion  envelope  antigens 
gp71,  gp43,  and pl5(E)  (18). The predominant natural  antibody titer of sera from most 
inbred strains is directed against gp71  (20) and is primarily type specific for the endoge- 
nous ecotmpic viruses (19, 20). As a result of the humoral immune response against gp71 
most  autogenous  immune  sera  are  cytotoxic  against  a  variety  of tumors  replicating 
MuLV and can neutralize MuLV, 2 although the latter activity can only be demonstrated 
in vitro with rapidly harvested,  unfrozen virus preparations.  The antibody titer against 
pl5(E) is generally less than the titer against gp71 and is predominantly group specific. 
This  reaction  is the  basis  of the  cross-reactivity  of autogenous  immune  sera with the 
Friend-Moloney-Rauscher  group  of viruses  (19).  The  consequences  of antibody  against 
pl5(E) are not known, but in general this antibody response is not associated with either 
neutralization  or cytotoxicity. 3 The  antibody  titer against  gp43  has  been  shown  to  be 
relatively low (18) and the consequences of this recognition are presently unknown. 
Although the immunological properties described above suggest the potential 
significance of a humoral immune response in regulating virus-mediated patho- 
genesis,  the  presence  of antibody  also  provides  a  convenient  assay  for  the 
expression  of endogenous  MuLV.  In  particular,  recent  studies  have  demon- 
strated a good correlation between the presence of antibodies and the expression 
of infectious ecotropic MuLV in vivo (22-24).  We have found that the antibody- 
positive  phenotype  segregates  with  the  viral  genome  in  several  crosses  of 
ecotropic virus-positive strains with strains that genetically lack this virus. The 
sequential sampling of individual mice for antibody can also provide informa- 
tion about the strain-dependent phenotypes for expression of ecotropic viruses 
(24).  Because of the above considerations,  we examined the humoral immune 
response in irradiated C57BL/6 mice to assess the role of irradiation in activat- 
ing endogenous ecotropic viruses and to determine the influence of this immune 
response on the development of thymic lymphomas. The results presented here 
demonstrate  that  irradiation  consistently  accelerates  the  appearance  of an 
immune  response  to  the  endogenous  ecotropic  virus  but  that  this  immune 
response, under various conditions, has no influence on nor correlation with the 
development of leukemia. 
Materials  and Methods 
Animals.  Male C57BL/6 mice were used in these studies. All mice were specific pathogen free 
and  were obtained from the central animal facility of the Frederick Cancer Research Center, 
Frederick, Md. 
Viruses.  Friend MuLV was obtained from the Eveline cell line, which was derived from the 
STU mouse strain (25). AKR MuLV was isolated from an established line of AKR mouse embryo 
cells that spontaneously initiated virus synthesis. C57L xenotropic virus was obtained from D17a 
dog sarcoma cells infected with a xenotropic virus from an X-ray-induced lymphoma of a  C57L 
mouse.  RADLV was isolated from C57BL/Ka  fibroblast cultures infected with in vivo derived 
RADLV. These cultures were at passage 11 after infection when used and were kindly provided by 
Dr. A. DeCleve, Stanford University, Stanford,  Calif. All viruses were purified by velocity and 
equilibrium density gradient centrifugation,  as previously described  (17,  18). Radioactive virus 
([3H]leucine) was prepared as previously described (17,  18). 
Radioimrnune Precipitation Assays.  Double-antibody radioimmune precipitation (RIP) assays 
for antibodies against gp71  and the preparation of AKR MuLV and Rauscher MuLV gp71  have 
2 Ihle, J.  N., and B. Lazar. Manuscript in preparation. 
3 Ihle, J. N., K. Bengali, and J. Domotor, Jr. Manuscript in preparation. JAMES  N.  IHLE,  ROBERT  McEWAN,  AND  KATHLEEN  BENGALI  1393 
been  previously  described  (20).  The RIP  assay  against intact  radioactively  labeled  AKR virus  was 
performed as previously  described (17)  and competition RIP assays with intact  virus  were com- 
parable to  those previously  reported (19). 
Radiation.  Mice were irradiated  with the doses and at the ages indicated in the Results 
section.  In  general,  4-wk-old  C57BL/6  mice  were  irradiated  four  times  at  175  R at  weekly  intervals. 
The source was a Phillips  MG  301 X-ray therapy unit (Phillips  Electronic  Instruments, Mount 
Vernon, N. Y.) with a 0.2  mm 3  filter  operated at 10 mA  and 300 kV. 
Bone  Marrow  Reconstitution. The day after  the  last  irradiation,  the mice were given 1 × 107 
bone  marrow cells  from 4-wk-old  C57BL/6 mice  by  intravenous injection.  C57BL/6 mice, 8-wk  old, 
which had received  no irradiation  were also  given  bone marrow cells  and served as controls. 
Results 
The development of antibody to MuLV in C57BL/6 mice after irradiation is 
shown in Fig. 1. In these experiments, 4-wk-old C57BL/6 mice were irradiated 
four times at weekly intervals with 175 R. Serum samples were collected from 
individual, ear-marked mice at monthly intervals starting at 1 mo of age and 
were assayed for the presence of antibodies to MuLV in a RIP assay. The results 
are  plotted  as  the  percentage of mice that  developed detectable antibodies 
against  MuLV.  The  immune response  to  MuLV  in  control,  nonirradiated 
C57BL/6 mice developed slowly and by 6 mo of age approximately 50% of the 
mice had developed detectable antibodies. These results are comparable to those 
previously reported for C57BL/6 mice and are different from the serological 
patterns observed with other inbred strains of mice (24). The appearance of 
antibodies to MuLV significantly increased in irradiated C57BL/6 mice and by 
2-3 mo after irradiation approximately 90% of  the mice had developed detectable 
antibodies to MuLV. These results agree with previous results, which suggested 
that radiation activates latent endogenous MuLV (5-7). In our experiments this 
activation was manifested by the development of an immune response to the 
virus. 
To rule out the possibility that irradiation might have suppressed the extent 
of the humoral immune response in irradiated mice, we examined the distribu- 
tion of titers of sera from control and irradiated mice, which had detectable 
antibody for three consecutive months. This time point was chosen because it 
reflects fully developed immune capacities and in irradiated mice corresponds to 
the time of tumor development. The titers of immune sera from irradiated and 
control mice were comparable and were generally 1:1,280-2,560 (Fig. 2). There- 
fore, irradiation enhanced the rate of appearance of  antibody against MuLV, but 
did not affect the peak titers. 
Previous studies have shown that the immune response to MuLV has both 
type-specific and group-specific immunological recognition of MuLV  (19). In 
order to establish the serological characteristics in irradiated C57BL/6 mice, we 
examined the antibody specificity by competition assays. The results of typical 
virus  competition  assays  are  shown  in  Fig.  3.  In  these  assays,  sera  from 
irradiated C57BL/6 mice were reacted at limiting dilutions with labeled AKR 
MuLV, and the ability of in vitro passaged RADLV (a B-tropic C57BL/Ka virus), 
an AKR N-tropic virus, a xenotropic virus from C57L mice, and Friend MuLV to 
compete was examined. Both the in vitro passaged RADLV and the AKR N- 
tropic virus competed completely and equivalently, suggesting that the major 
antigenic determinants involved in the immunologic  recognition of  these viruses 100. 
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FIo.  1.  Development of antibody against MuLV in control and irradiated C57BL/6 mice. 
Groups of 50 C57BL/6 mice at 1 mo of age were either irradiated with 175 R four times at 
weekly intervals, (@--0); or served as unirradiated controls, (©--O). Beginning at i  mo of 
age and subsequently at monthly intervals serum samples were collected from individual 
mice by tail bleeding and were tested in a  RIP assay at a  1:40 serum dilution for antibodies 
against MuLV. The results are plotted as the percentage of mice having developed detecta- 
ble antibodies against MuLV vs. age. 
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Fro.  2.  Antibody titer of control and irradiated C57BL/6 mice against MuLV. Sera from 
individual control  C57BL/6 mice and mice irradiated  at  1 mo with  175 R  four times at 
weekly  intervals,  which had been positive for antibodies against MuLV for 3  mo,  were 
titered in a RIP assay, as previously described (17,  18). The titer of a serum is that dilution 
giving 50% of maximal precipitation of labeled virus. 
by C57BL/6 mouse sera were identical. In contrast, neither the xenotropic C57L 
virus nor Friend MuLV could compote in this assay, demonstrating that the 
humoral immune response detectable in RIP was specifically directed against 
the endogenous ecotropic virus. These results agree with previous results using JAMES  N.  IHLE,  ROBERT  McEWAN,  AND  KATHLEEN  BENGALI  1395 
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FIG. 3.  Competition RIP assays of a serum from an irradiated C57BL/6 mouse. Serum 
from an irradiated  C57BL/6 mouse was reacted with [3H]leucine-labeled  AKR  MuLV  at a 
dilution of 1:200  in the presence of decreasing concentrations of AKR  MuLV,  (O--©); in 
vitro  pasaged RADLV,  (0--0); C57L xenotropic virus,  (A--A); and Friend MuLV, (A--A), 
as previously described (19).  Control precipitation  in  the absence of  competing antigen was 
approximately 70%. Comparable curves were obtained with various additional individual 
sera. 
sera from irradiated C57BL/6 mice (26) and are also comparable to the results 
obtained with sera from nonirradiated control C57BL/6 mice (19). 
The predominant immunological reaction obtained with most autogenous 
immune sera is against the ecotropic viral gp71 and is type specific  (19, 20). 
Since the glycoprotein of RADLV appears completely homologous to AKR viral 
glycoprotein (accompanying paper), we examined sera from irradiated C57BL/6 
mice for the presence of antibodies capable of  reacting with AKR MuLV gp71. As 
demonstrated in  Table  I,  immune sera  from irradiated  C57BL/6 mice had 
demonstrable antibodies capable of precipitating AKR MuLV gp71. In contrast, 
none of these sera had detectable reactivity against Rauscher MuLV gp71 (data 
not shown). Moreover, there was a  good correlation between positivity in the 
RIP assay and the presence of antibody capable of reacting with AKR MuLV 
gp71. These results are similar to those previously reported (14, 26) and further 
suggest that the immune response detectable in irradiated C57BL/6 mice is 
specifically directed against the endogenous ecotropic virus. 
The correlation between the development of a humoral immune response and 
lymphoma is shown in Tables II and HI. In Table II the representative serologi- 
cal histories of individual mice that  died from lymphoma are tabulated.  In 
general, three distinct types of immunological patterns were observed during 
the course of irradiation and tumor development: (a) One group of mice showed 
no detectable immune response throughout the course of the experiment and 
later died;  (b)  a  second group transiently developed a  humoral immune re- 
sponse, but later died without any detectable antibodies; (c) most mice, however, 
developed a persistent humoral immune response and later died with detectable 1396  LACK  OF  SEROLOGICAL  EVIDENCE  FOR  MuLV  IN  C57BL/6  THYMOMAS 
TABLE I 
Comparison  of Titers of Sera from Irradiated C57BL/6 Mice 
against Labeled AKR MuLV and AKR MuLV gp71 
Serum no. 
Titer* 
AKR MuLV  AKR MuLV gp71 
1  0  <1:10 
2  0  <1:10 
3  1:640  1:20 
4  1:640  1:20 
5  1:640  1:40 
6  1:1,280  1:40 
7  1:1,280  1:80 
8  1:1,280  1:60 
* Sera were titered as described in Materials and Methods. Serum titers 
against AKR MuLV are defined as the serum dilution  precipitating 
50% of the labeled virus.  Serum titers against AKR MuLV gp71 are 
defined  as  the  serum  dilution  precipitating  25%  of the  maximum 
antigen precipitated with a  xenagenic antiserum against AKR MuLV 
gp71. 
TABLE  II 
Anti-Viral Antibody Distribution  During the Life Span of Individual Irradiated 
C57BL/6 Mice that Died from Lymphomas* 
Antibody titer$ 
Mouse no.  Age (mo) 
1  2  3  4  5  6  Titer at 
death 
1  0  0  0  0  0  0  0 
2  <1:40  0  0  0  0  0 
3  0  0  0  0  >1:40  0  0 
4  0  0  0  <1:40  >1:40  <1:40  0 
5  0  0  <1:40  <1:40  0  0 
6  <1:40  >h40  0  0  0  0  0 
7  0  0  0  0  <1:40  1:160 
8  0  0  0  0  <1:40  >1:40  1:160 
9  <1:40  0  <1:40  <1:40  >1:40  <1:40  1:320 
10  0  0  <1:40  >1:40  >1:40  1:1,280 
11  0  0  0  <1:40  >1:40  >1:40  1:2,560 
12  0  0  0  <1:40  <1:40  1:2,560 
13  <1:40  0  <1:40  0  >1:40  >1:40  1:1,280 
14  0  <1:40  <1:40  0  0  >1:40  hl,280 
15  0  0  0  0  0  >1:40  h640 
* C57BL/6 mice were tail bled at monthly intervals and serum collected for RIP assays. To induce 
leukemia, mice were irradiated with 175 R four times at weekly intervals starting at i  mo of age. 
Death from thymomas occurred during the 5th and 6th mo of age and sera were collected from 
moribund mice for RIP assays. 
$ Relative antibody titers against MuLV were determined by RIP assays at a  1:40 serum dilution. 
Sera precipitating greater than 50% of the labeled virus were considered to have titers  >1:40, 
whereas sera precipitating less than 50% of the virus but more than 10% above background were 
considered to have titers of <1:40. JAMES  N.  IHLE~  ROBERT  McEWAN~  AND  KATHLEEN  BENGALI  1397 
TABLE  III 
Incidence of Radiation-Induced Lymphomas Among C57BL/6 Mice of Different 
Antibody Phenotypes* 
Antibody pheno-  Total, no./total  Lymphoma,  No lymphoma,  Lymphoma 
type  no./total  no./total  incidence 
% 
No antibody  4/49  3/32  1/17  75 
Transient antibody  9/49  6/32  3/17  66.7 
Persistent antibody  36/49  23/32  13/17  63.9 
Combined  49/49  32/49  17/49  65.3 
* C57BL/6 mice were irradiated with 175 R four times at weekly intervals beginning at 1 mo of 
age.  All  mice  were  individually  tested  for  antibodies  against  MuLV  at  monthly  intervals 
starting at I mo of age, Tumor-bearing mice were those that died of thymomas 5 mo after the last 
irradiation,  whereas  tumor-free  mice  were  those  surviving 5  mo  after the  last  irradiation. 
Antibody phenotypes were: no antibody, lack of detectable antibody during the entire experi- 
mental period; transient antibody, detectable antibody only occasionally during the course of the 
experiment; and persistent antibody, antibody detectable consistently from the time of its first 
appearance  (see Table I).  Antibody positivity was determined by RIP assays at a  1:40  serum 
dilution. Sera precipitating virus above background levels were considered positive. 
levels of antibody to MuLV. The distribution of these types of immune responses 
in mice dying of lymphomas and mice living at least 5 mo postirradiation is 
summarized in Table III. Only 4/49 mice never developed any detectable anti- 
body throughout the period of observation; nevertheless, within this group 3/4 
mice developed lymphomas and died. A larger group of mice (9/49) developed 
detectable antibody transiently during the period of observation, and the fre- 
quency of tumors in such mice was approximately 67%. The majority (36/49) of 
mice developed a  persistent immune response to the virus and,  of these 36, 
approximately 64% developed tumors.  Of the mice with thymomas, approxi- 
mately 28% were antibody negative and 72% were antibody positive at death. 
These results suggest that there is little or no correlation between the develop- 
ment and maintenance of an immune response to the virus and the occurrence  of 
lymphoma. 
Kaplan (27) has demonstrated an age-associated incidence of lymphomas in 
irradiated C57BL/6 mice. We, therefore, examined the correlation of age and the 
development of a humoral immune response. As illustrated in Fig. 4, there were 
no apparent differences  in either the rate of development of an immune response 
in mice irradiated at 4, 8, 12, or 16 wk of age or in the range oftiters of anti-viral 
antibodies among the various age groups (data not shown).  In contrast, age 
profoundly influenced the incidence of irradiation-induced lymphomas (Table 
IV). At 6 mo postirradiation, the incidence of thymomas was 75, 53, 25, and 20% 
for the 4-, 8-, 12-, and 16-wk-old groups, respectively. Although these results are 
comparable to those initially reported by Kaplan (27), they suggest that the age 
dependence for induction of thymomas is not associated with differences in the 
immune response to the virus. 
Previous studies have demonstrated that bone marrow reconstitution of irra- 
diated mice can suppress the development of leukemias (28). We,  therefore, 
examined bone marrow-reconstituted  mice for differences  in the appearance and 
titer of antibodies to MuLV. As illustrated in Table V, bone marrow reconstitu- 1398  LACK  OF  SEROLOGICAL  EVIDENCE  FOR  MuLV  IN  C57BL/6 THYMOMAS 
100- 
90- 
80. 
-=i 70-  60. 
50- 
40- 
30, 
20- 
10- 
Age (month,=) 
FIG.  4.  Age dependency of the radiation-induced appearance of antibody against MuLV. 
Groups of antibedy-negative 1-, (@--@, 20 mice); 2-, (O--©, 15 mice); 3-, (/x--A, 20 mice); or 
4-mo-old ([:]--D,  20 mice) C57BL/6 mice were irradiated with 175 R  four times at weekly 
intervals. Sera were collected at monthly  intervals and tested at a 1:40 serum dilution in the 
RIP assay for antibodies against MuLV. The results are presented as the percentage of mice 
developing an immune response against MuLV vs. age. 
TABLE  IV 
Thymoma Incidence in C57BL/6 Mice Irradiated at Various Ages* 
Lymphoma incidence 
Age at ir- 
radiation  Months postirradiation 
1  2  3  4  5  6 
mo 
1  0/20  7/20  13/20  15/20  15/20  15/20 
2  0/15  1/15  3/15  7/15  8/15  8/15 
3  0/20  0/20  1/20  2/20  4/20  5/20 
4  0/20  0/20  2/20  3/20  4/20  4/20 
* C57BL/6 mice at 1-4 mo of age were irradiated four times at weekly intervals with 175 R. 
TABLE V 
Thymoma Incidence in Control and Bone Marrow-Reconstituted C57BL/6 Mice* 
Irra- 
Group  B.M. 
diated 
Lymphoma incidence 
Months postirradiation 
1  2  3  4  5  6  7  8 
I  -  -  0110  0/10  0/10  0/10  0/10  0t10  0/10  0110 
2  +  -  0/10  0110  0/10  0/10  0/10  0t10  0/10  0/I0 
3  -  +  0/15  0/15  0/15  5/15  11/15  12/15  12/15  12/15 
4  +  +  0/15  0/15  0/15  0/15  0/15  0/15  0/15  0/15 
* 4-wk-old C57BL/6 mice were used at the start of the experiments in all groups. Irradiation (175 
R) was given four times at weekly intervals. Bone marrow reconstitution was at 2 mo of age after 
the last irradiation with 1 x  107 bone marrow cells from 4-wk-old C57BL/6 mice. JAMES  N.  IHLE,  ROBERT  McEWAN,  AND  KATHLEEN  BENGALI  1399 
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FIG.  5.  Influence of bone marrow reconstitution on the appearance of antibodies against 
MuLV after irradiation. C57BL/6 mice were irradiated at 1 mo of age with 175 R four times 
at weekly intervals. One group of mice (15) was given 1 x  l0  T  syngeneic bone marrow cells 
immediately  after  the  last  irradiation,  (O--O);  and  a  second  group  of mice  was  not 
reconstituted,  (@--@).  Serum was collected at  monthly intervals by  tail  bleeding and 
assayed at  a  1:40 serum  dilution for antibodies against  MuLV  in  the  RIP  assay.  The 
results are presented as the percentage of mice developing an immune response against 
MuLV vs. age. Control nonirradiated, and nonirradiated bone marrow-treated mice devel- 
oped antibodies identical to the controls illustrated in Fig. 1. 
tion completely suppressed the occurrence of thymic lymphomas. This suppres- 
sion occurred without any detectable difference in the rate of appearance of a 
humoral immune response against the virus (Fig. 5). Moreover, when sera from 
mice, which had developed a humoral immune response against the virus, were 
titered, bone marrow-reconstituted mice generally had titers of 1:320-640 (data 
not shown), which are only slightly less than the titers of control mice. These 
results suggest that the suppression of leukemia by bone marrow reconstitution 
is not related to its potential influence on the humoral immune response against 
the virus. 
The  effect  of the  cumulative  dose  of irradiation  on  lymphomas  and  the 
humoral immune response is shown in Fig. 6. Mice given either two, three, or 
four treatments of 175 R developed comparable immune responses both in the 
rate and extent of appearance of antibody. In contrast,  with mice given 175 R 
once, only approximately 35% of the population developed detectable antibodies 
but at a rate comparable to the other groups. Sera from mice of all groups were 
also titered, and no significant differences were observed (data not shown). The 
incidence of lymphoma,  as  shown in  Table VI,  decreased with  a  decreasing 
cumulative dose. Thus, as above, there was no correlation between the appear- 
ance of an immune response to MuLV and development of lymphomas. 
Discussion 
The  existence  and  characteristics  of a  humoral  immune  response  against 
endogenous ecotropic viruses in a  variety of inbred strains of mice have been 1400  LACK OF  SEROLOGICAL EVIDENCE FOR  MuLV IN  C57BL/6 THYMOMAS 
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Fro.  6.  Influence of dose of irradiation  on the appearance  of antibodies against MuLV. 
C57BL/6 mice at 1 mo of age were given one, (Q--O); two, (O--O); three,  (A--A); or four, 
(A--A) treatments of 175 R at weekly intervals.  Sera were collected at monthly intervals 
and tested at a 1:40 serum dilution for antibodies against  MuLV with the RIP assay. The 
results  are presented as the percentage of mice developing an immune response against 
MuLV vs. age. 
TABLE VI 
Incidence of Lymphoma in C57BL/6 Mice Given Various Doses of Irradiation* 
Treatment 
Thymoma incidence 
Months postirradiation 
1  2  3  4  5 
1 × 175R  0/25  0/25  0/25  0/25  0/25 
2 × 175R  0/25  0/25  2/25  3/25  3/25 
3 x 175R  0/25  0/25  0/25  1/25  1/25 
4 × 175R  0/17  0/17  3/17  7/17  12/17 
* C57BL/6 mice, 1 mo of age, were given one to four treatments of 175 R at weekly intervals. 
amply demonstrated  (17-21).  The present  study was undertaken to determine 
the influence of this immune response on endogenous ecotropic virus-mediated 
disease.  Radiation-induced leukemia in C57BL/6 mice was chosen for various 
reasons including: (a) the lack of chronic viremia such as that found in the AKR 
mouse,  which might preclude  the  detection of free  antibody;  (b)  the  existing 
hypothesis that radiation  activates latent  endogenous viruses,  which in turn 
induce leukemia; and (c) the availability of a variety of experimental manipula- 
tions that  influence  the  development of leukemia,  some of which have been 
interpreted  as being immunological. The results of our experiments were  (a) 
radiation consistently accelerates the appearance of an immune response to the 
endogenous ecotropic virus, and (b) this immune response, under various condi- 
tions, has no correlation with nor influence on the development of leukemia. 
The ability of irradiation to accelerate the natural appearance of the humoral 
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endogenous MuLV. This conclusion is supported by recent results, which have 
demonstrated a  correlation between the presence of antibody and infectious 
ecotropic MuLV (22, 23) and by genetic experiments designed to map the viral 
genome of a variety of inbred strains of mice and to study the phenotypes for 
virus expression (reference  24 and footnote 3). Therefore, our results are compat- 
ible  with earlier work,  (5-7,  12), which suggested that  one  consequence of 
irradiation was the activation of endogenous MuLV. Our results also suggest 
that this activation requires only minimal doses of irradiation, is independent of 
age, and is independent of experimental manipulations which suppress leuke- 
mia, such as bone marrow reconstitution. 
Although radiation accelerated the appearance of antibody against MuLV, 
the humoral immune response had no apparent influence on the incidence of 
leukemia.  Thus,  irrespective of whether an  immune response developed or 
persisted after irradiation, the incidences of leukemia were comparable. These 
results are in contrast to previous studies which suggested immune regulation 
of leukemia via viral antigenic determinants (29, 30). The occurrence of leuke- 
mia in irradiated mice, which never developed detectable antibodies against 
MuLV,  is of particular interest. In these cases, either there was insufficient 
viral expression to stimulate an immune response, or in these mice there was no 
detectable antibody because of viremia. As demonstrated in the accompanying 
paper, viremia was not detectable in such mice. The most likely explanation for 
the lack of antibody in these mice is that there was an insufficient level of 
activation of MuLV to induce an immune response. Clearly, however, radiation 
still effectively induces leukemia. 
Another characteristic immune response in irradiated mice was the transient 
development of antibody against MuLV. This pattern is also characteristic of 
nonirradiated C57BL/6 mice and,  in general, is characteristic of the immune 
response in  inbred strains in which antibody against MuLV appears slowly 
during their life span2 This type of response could be due to either transient 
viremia or waning of the immune response due to a  lack of persistent virus 
expression. That this response is not due to viremia is indicated in the accompa- 
nying paper. Thus, we feel that the transient appearance of antibody probably 
reflects the transient expression of virus with subsequent waning of  the immune 
response. This conclusion is supported by the observation that introduction of a 
constitutively  expressed viral genome into C57BL/6 mice by the cross C57BL/6 × 
AKR or C57BL/6 × C3H results in the appearance of antibodies early in life, at 
high titers, which persist for the life span of the hybrid (J. N. Ihle, K. Bengali, 
and J. Domotor, Jr., unpublished data). Nevertheless, the results demonstrate 
that whether or not the immune response persists in irradiated mice, there is no 
influence on the incidence of leukemia. 
The lack of correlation of  the serological data with the development  oflympho- 
mas could have been due to the inability of our assays to detect antibodies 
serologically specific for the endogenous ecotropic virus associated with radia- 
tion  leukemia.  This  does  not  appear  to  be  the  case,  however,  since  virus 
competition assays demonstrated that,  in terms of the humoral immune re- 
sponse, in vitro passaged RADLV was serologically equivalent to the AKR-type 
virus. In addition, these assays have demonstrated that the immune response is 
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of mice. Thus, assuming the ecotropic virus is the causative agent of radiation 
lymphomas, we might have expected a correlation. 
A lack of correlation between antibody and the incidence of lymphoma could 
have been due in part to the absence of overt ecotropic virus expression in the 
majority of radiation-induced lymphomas (accompanying paper). This observa- 
tion, however, does not preclude the virus as the etiological agent, in that once 
transformation has occurred overt expression may not be necessary and, in fact, 
in an immunologically competent animal the expression of viral antigens may 
be selected against.  The data presented here, however, suggest that if virus 
expression is at all required, then this expression might not be sufficient to 
induce an immune response and,  as shown in the accompanying paper, that 
even in the  absence of a  humoral immune response, thymomas may fail to 
express MuLV. Thus, from a seroepidemological perspective there is no demon- 
strable correlation between endogenous ecotropic viruses and radiation-induced 
lymphomas. 
Our  results  are  of particular significance when considering the  potential 
immunological mechanisms in  the  induction of radiation leukemia,  and  in 
general demonstrate that the radiation regimen used in these experiments is 
not immunosuppressive insofar as  development of the humoral immune re- 
sponse against endogenous MuLV is concerned. Of particular interest was the 
observation that although bone marrow reconstitution of irradiated mice did not 
significantly alter the  immune response to MuLV,  it completely suppressed 
subsequent leukemia. Therefore, neither radiation-induced leukemia nor its 
suppression by bone marrow reconstitution appears to be due to their influence 
on the humoral immune response against MuLV. 
The results presented here and in the accompanying paper also suggest that 
any immunological approach via viral antigens to  control radiation-induced 
leukemia will not be successful. In fact, previous attempts using passive immu- 
nization against MuLV have proven equivocal (31) and attempts at immuniza- 
tion have not succeeded (32). This conclusion is also supported by the lack of an 
influence of the humoral immune response as demonstrated here, in spite of the 
fact that this immune response has been shown to be capable of being cytotoxic 
for virus-replicating cells and of  neutralizing MuLV. The efficacy  of an immuno- 
logical approach is also questioned by the lack of overt virus expression in the 
majority of radiation-induced leukemias, as shown in the accompanying paper. 
In conclusion, the results have demonstrated the lack of a serological relation- 
ship between the  immune response to  endogenous ecotropic MuLV and the 
development of thymic lymphomas, and reasonably question the etiological role 
of endogenous MuLV in radiation-induced leukemias in C57BL/6 mice. Clearly, 
however, additional experiments are necessary to further examine the role of 
these viruses in radiation leukemia. 
Summary 
The humoral immune response against endogenous ecotropic murine leuke- 
mia viruses (MuLV)  was examined in irradiated and control C57BL/6 mice. 
Control mice developed antibodies against MuLV slowly throughout life.  In 
contrast, within 2-3 mo after irradiation 90% of irradiated C57BL/6 mice had JAMES  N.  IHLE,  ROBERT  McEWAN,  AND  KATHLEEN  BENGALI  1403 
developed detectable antibodies against MuLV. The characteristics of this im- 
mune response, however, were identical in control and irradiated mice in terms 
of  peak titers, specificity for endogenous ecotropic MuLV, and reactivity against 
the ecotropic viruses' glycoprotein (gp71).  Moreover, the rate of appearance of 
antibodies against MuLV in irradiated mice and the peak titers were generally 
not  affected by  age  at  irradiation,  dose  of irradiation  (two,  three,  or  four 
treatments of 175 R), or bone marrow reconstitution. 
Although the ability of  irradiation to accelerate the appearance of  antibody in 
a  population  of C57BL/6  mice  suggested  activation of endogenous ecotropic 
MuLV,  there  was  no  apparent  correlation  between  the  appearance  of this 
immune response or its persistence and the development of lymphoma. Thus, 
the  incidence of lymphoma was  comparable  in  mice  that:  (a)  developed no 
immune response;  (b)  developed an  immune response  only transiently after 
irradiation; or (c) developed an immune response which persisted until death 
from lymphoma. Moreover, experimental conditions that alter the ability of 
irradiation to induce leukemia, such as age, dose, or bone marrow reconstitution 
did so without significantly altering either the rate of appearance of a humoral 
immune response to  MuLV or its peak  titers.  The results,  therefore, fail to 
demonstrate any seroepidemological relationship between endogenous ecotropic 
MuLV and radiation-induced leukemia. 
Received for publication 24 June 1976. 
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